Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura.
Human immunoglobulin was administered intravenously to nine adult patients having severe chronic immune thrombocytopenia purpura. The response in three patients was an increase in the platelet count to greater than 50,000/mm3, a hemostatically adequate level. Response was associated with a pretreatment platelet-associated immunoglobulin level of more than 5,000 molecules per platelet, and successful treatment resulted in a decrease in that level. In those patients with pretreatment platelet-associated immunoglobulin levels less than 5,000 molecules per platelet, there was neither a significant decrease in that level nor an increase in their platelet count. Immunoglobulin infusion may prove useful for selected patients with severe chronic immune thrombocytopenia.
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000276:immunology; D002908:Chronic Disease; D003298:Coombs Test; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D016756:Immunoglobulins, Intravenous; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000276:immunology / Q000628:therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous